NCT04681092View on ClinicalTrials.gov

Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

AKS-452

s.c. or i.m. vaccination

Trial Locations (1)

9700 RB

University Medical Center Groningen, Groningen

Sponsors
All Listed Sponsors
collaborator

Akston Biosciences Corporation

UNKNOWN

lead

University Medical Center Groningen

OTHER

NCT04681092 - Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study | Biotech Hunter | Biotech Hunter